Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript October 31, 2024Travere Therapeutics, Inc. misses on earnings expectations.
Travere Therapeutics Inc. (TVTX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 56,031,000 | $53,537,621 | 1.51% | ||
| 2. | 30,000 | $28,598 | 0% | ||
| 3. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.85 | 5,000 | Officer, Director | 245,556 | 2017-06-14 | Filing | |
| $15.31 | 5,000 | Director | 52,000 | 2016-03-04 | Filing | |
| $8.60 | 15,000 | Director | 35,000 | 2014-11-25 | Filing | |
| $8.38 | 6,100 | Director | 129,165 | 2014-11-21 | Filing | |
| $8.50 | 8,700 | Officer, Director | 371,756 | 2014-11-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.15 | 18,821 | 51,000 | 2024-10-04 | Filing | ||
| $14.35 | 21,179 | 69,821 | 2024-10-04 | Filing | ||
| $14.06 | 40,000 | 81,000 | 2024-09-30 | Filing | ||
| $12.98 | 684 | 61,949 | 2024-09-10 | Filing | ||
| $11.52 | 4,387 | 84,455 | 2024-09-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,080,000 | $2,591,204 | 0% | |
| 2. | Morgan StanleyBOND | 2,834,000 | $2,401,815 | 0% |
| 3. | Css LlcBOND | 2,500,000 | $2,113,110 | 0.12% |
| 4. | 30,000 | $25,239 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
10 Best Biotech Stocks To Buy Under $20
The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative treatments, technological advancements, and government support.
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Travere Therapeutics' Second Quarter 2024 Financial Results and Corporate Update Conference Call. Today's call is being recorded.
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript
Travere Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.7639 EPS, expectations were $-0.98. Travere Therapeutics, Inc.
5 Best Biotech Stocks To Buy Under $20
In this article, we are going to take a closer look at five best biotech stocks to buy under $20.
5 Best Medical Stocks to Buy Under $10
In this article, we will take a look at the 5 best medical stocks to buy under $10.
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2023 Earnings Call Transcript
Operator: Good day and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference Call. Today's conference is being recorded.
5 Small-Cap Stocks with High Potential
In this article, we will take a look at the 5 small-cap stocks with high potential.
5 Best Falling Stocks To Buy Now
In this piece, we will take a look at the five best falling stocks to buy now.
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2023 Earnings Call Transcript
Operator: Good day, and welcome to the Travere Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call. Today's conference call is being recorded.
Billionaire Hedge Funds
